Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA to Acquire Cequent in $46M Stock Deal


MDRNA has agreed to acquire privately held RNAi drug shop Cequent Pharmaceuticals in an all-stock deal valued at roughly $46 million, the companies said this week as RNAi News went to press.

Through the transaction, MDRNA will gain Cequent's orally delivered transkingdom RNAi technology, which involves using attenuated Escherichia coli to transcribe therapeutic shRNAs.

In addition, MDRNA will pick up Cequent's RNAi-based treatment for advanced familial adenomatous polyposis, which is slated to enter phase I testing this year, and an earlier-stage program in inflammatory bowel disease.

The combined company is expected to be headquartered in Bothell, Wash., where MDRNA is located, with MDRNA's President and CEO Michael French leading the new firm. Cequent's President and CEO Peter Parker will become chairman of the merged company.

Under the terms of the transaction, each outstanding share of Cequent common stock will be exchanged for MDRNA common stock at an exchange ratio that "implies a purchase price for Cequent shareholders of approximately $44 million, plus an additional value of $2 million to warrant and option holders," the companies said.

The deal is expected to close in July.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.